Could a Brain-Targeting drug ease Parkinson's dementia symptoms?
NCT ID NCT04470037
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested a drug called DAAOI-P in 61 people with Parkinson's disease who also have dementia. The goal was to see if the drug could improve walking, reduce falls, and ease neuropsychiatric symptoms. Participants received either DAAOI-P or a placebo pill for a period, and changes were measured using standard rating scales.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- DAAOI-P (a drug that modulates NMDA receptors)
- What this could lead to
- If successful, DAAOI-P could offer a new treatment option to improve movement and behavioral symptoms in people with Parkinson's dementia.
- What could go wrong
- This is a small Phase 2 trial with only 61 participants, so results may not apply to everyone. The drug may not show clear benefits or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
61 people
The number who actually took part.
- Started
-
Apr 2016
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * PD-D will be diagnosed according to the criteria proposed by Movement Disorder Society task force statement. (Emre et al. 2007) . The following wordings are modified from the task force statement. I. Core features 1. Diagnosis of PD according to Queen Square Brain Bank criteria 2. A dementia syndrome with insidious onset and slow progression, developing within the context of established PD and diagnosed by history, clinical, and mental examination, defined as: * Impairment in more than one cognitive domain * Representing a decline from premorbid level * Deficits severe enough to impair daily life, independent of the impairment ascribable to motor or autonomic symptoms * MMSE score between 10-26. II. Associated clinical features 1. Cognitive features: Impaired attention, executive functions, visuo-spatial functions or memory. Core functions of language are largely preserved. 2. Behavioral features: * Apathy * Changes in personality and mood * Hallucination• Delusions * Excessive daytime sleepiness III. Features which do not exclude PD-D, but make the diagnosis uncertain * Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not to be the cause of dementia. * Time interval between the development of motor and cognitive symptoms is uncertain IV. Features suggesting other conditions or diseases as cause of mental impairment, which, when present make it impossible to reliably diagnose PD-D * Cognitive and behavioral symptoms appearing solely in the context of other conditions such as: 1. Acute confusion due to systemic illnesses or drug intoxication. 2. Major depression * Features compatible with "Probable Vascular dementia" criteria according to NINDS-AIREN Criteria for the diagnosis of probable and possible PD-D \[Probable PD-D\] Both core features must be present. In associated clinical features, typical profile of cognitive deficits should be present in at least 2 of the 4 core cognitive domains. The presence of at least one behavioral symptom supports the diagnosis of probable PD-D. None of group III and IV features is present. \[Possible PD-D\] Both core features must be present. In associated clinical features, the cognitive impairment is atypical in one or more domains. The behavioral symptoms are not necessary to be present. One or more of the group III features may be present. No group IV feature is allowed to be present. Exclusion Criteria: 1. Patients with uncontrollable malignancy, severe heart failure, uremia under hemodialysis, or decompensated liver cirrhosis. 2. Patients taking anticholinergics within 30 days of recruitment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease dementia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hunger hormone levels in blood may reveal dementia type
- New brain scan could spot Parkinson's earlier
- New study aims to ease caregiver stress through smart matching
- Can a compound in grapes help Parkinson's? new trial launches
- Peer support trial aims to ease the heavy burden on lewy body dementia caregivers
- Online support groups and telemedicine aim to ease Parkinson's and dementia burden